HomeCMVLF • OTCMKTS
add
Cellectis SA
Previous close
$1.25
Year range
$1.25 - $1.50
Market cap
105.28M USD
Avg Volume
13.00
P/E ratio
-
Dividend yield
-
Primary exchange
EPA
Market news
Financials
Income Statement
Revenue
Net income
| (USD) | Mar 2025info | Y/Y change |
|---|---|---|
Revenue | 12.03M | 85.10% |
Operating expense | 26.21M | -4.33% |
Net income | -18.13M | -421.25% |
Net profit margin | -150.71 | -273.55% |
Earnings per share | -0.17 | -21.43% |
EBITDA | -11.13M | 39.30% |
Effective tax rate | — | — |
Balance Sheet
Total assets
Total liabilities
| (USD) | Mar 2025info | Y/Y change |
|---|---|---|
Cash and short-term investments | 127.64M | 3.79% |
Total assets | 364.09M | 2.72% |
Total liabilities | 247.88M | -6.07% |
Total equity | 116.20M | — |
Shares outstanding | 72.29M | — |
Price to book | 0.78 | — |
Return on assets | -9.48% | — |
Return on capital | -16.42% | — |
Cash Flow
Net change in cash
| (USD) | Mar 2025info | Y/Y change |
|---|---|---|
Net income | -18.13M | -421.25% |
Cash from operations | -17.16M | 26.40% |
Cash from investing | 4.22M | 305.90% |
Cash from financing | -4.09M | -134.38% |
Net change in cash | -15.62M | -13.67% |
Free cash flow | -7.10M | 83.60% |
About
Cellectis is a French biopharmaceutical company. It develops genome-edited chimeric antigen receptor T-cell technologies for cancer immunotherapy. It has offices in Paris, New York City, and Raleigh, North Carolina. Wikipedia
Founded
1999
Website
Employees
219
